Molecule
Gadodiamide is a paramagnetic contrast agent indicated for intravenous use to visualize lesions with abnormal vascularity in the brain, spine, and associated tissues, among other approved uses. It is available as injection for intravenous use. MedsAcross supplies Gadodiamide for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
OMNISCAN is a gadolinium-based contrast agent for diagnostic magnetic resonance imaging (MRI) indicated for intravenous use to: Visualize lesions with abnormal vascularity in the brain, spine, and associated tissues. Facilitate the visualization of lesions with abnormal vascularity within the thoracic, abdominal, pelvic cavities, and the retroperitoneal space
Source: US FDA prescribing information
CNS – Adults and Pediatrics, 2 to 16 years of age: 0.2 mL/kg (0.1 mmol/kg). Body – Adults and Pediatrics, 2 to 16 years of age: Kidney: 0.1 mL/kg (0.05 mmol/kg) Intrathoracic, intra-abdominal, and pelvic cavities: 0.2 mL/kg (0.1 mmol/kg)
Source: US FDA prescribing information
OMNISCAN is contraindicated in patients with: Chronic, severe kidney disease (glomerular filtration rate, GFR < 30 mL/min/1.73m 2 ) or acute kidney injury Prior hypersensitivity to OMNISCAN Patients with chronic, severe kidney disease (GFR < 30 mL/min/1.73m 2 ) or acute kidney injury.
Source: US FDA prescribing information
Boxed warning: Intrathecal administration of gadolinium-based contrast agents (GBCAs) can cause serious adverse reactions including death, coma, encephalopathy, and seizures. OMNISCAN is not approved for intrathecal use. GBCAs increase the risk for nephrogenic systemic fibrosis among patients with impaired elimination of the drugs. Hypersensitivity Reactions: Anaphylactoid and other serious hypersensitivity reactions including fatal reactions have occurred particularly in patients with history of allergy or drug reactions. Monitor patients closely for need of emergency cardiorespiratory support. Gadolinium Retention: Gadolinium is retained for months or years in brain, bone, and other organs. Acute Renal Failure: Acute renal failure has occurred in patients with preexisting renal insufficiency. Use the lowest necessary dose of OMNISCAN and evaluate renal function in these patients.
Source: US FDA prescribing information
The following clinically significant adverse reactions are discussed in greater detail in other sections of the label: Nephrogenic systemic fibrosis Hypersensitivity reactions Acute Renal Failure The most frequent adverse reactions (≤ 3%) observed during OMNISCAN adult clinical studies were nausea, headache, and dizziness. Serious or life-threatening reactions include: cardiac failure, arrhythmia and myocardial infarction
Source: US FDA prescribing information
Specific drug interaction studies have not been conducted.
Source: US FDA prescribing information
Store OMNISCAN at controlled room temperature 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
3 presentations of Gadodiamide, sorted by availability.
| Medicine | Manufacturer | Register | Availability |
|---|---|---|---|
| Omniscan 2870 mg/10 mL injectionIntravenous | GE Healthcare | US FDA | Available on request |
| Omniscan 4305 mg/15 mL injectionIntravenous | GE Healthcare | US FDA | Available on request |
| Omniscan 5740 mg/20 mL injectionIntravenous | GE Healthcare | US FDA | Available on request |
1 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 8 January 1993 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Yes, on request. MedsAcross lists 3 presentations of Gadodiamide and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 1 brand names for Gadodiamide, including Omniscan.
Yes. The US FDA first approved Gadodiamide on 8 January 1993, according to Drugs@FDA.
No listed presentation of Gadodiamide is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.